JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained an $8 price target.
June 30, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics' stock rating has been reiterated as 'Market Outperform' by JMP Securities, with a maintained price target of $8.
The reiteration of the 'Market Outperform' rating and maintained price target by JMP Securities indicates a positive outlook for Aquestive Therapeutics. This could potentially attract investors, leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100